Form 4: Aligos Therapeutics CFO Exchanges Stock Options in Company Program

Lesley Ann Calhoun, CFO of Aligos Therapeutics, participated in the company's option exchange program, resulting in the cancellation of existing stock options and the grant of new replacement options.

Summary

• Lesley Ann Calhoun, the CFO of Aligos Therapeutics, engaged in a transaction involving stock options.
• On February 27, 2024, Calhoun's existing stock options for 176,237 shares (exercise price $16.18), 105,000 shares (exercise price $3.06), and 26,250 shares (exercise price $3.06) were canceled as part of Aligos Therapeutics' option exchange program.
• On February 28, 2024, Calhoun received replacement options for 51,833 shares, 74,998 shares, and 18,750 shares, all with an exercise price of $0.96 per share.
• The new options vest over time, contingent on Calhoun's continued service with the company.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The option exchange could be seen as slightly positive for incentivizing management, but it's not a major event.

Positives

• The option exchange program may incentivize continued service by key personnel like the CFO.
• The lower exercise price of the new options ($0.96) could be seen as a positive for the recipient, making them more likely to be exercised if the stock price increases.

Negatives

• The cancellation of existing options could be perceived negatively if the original exercise prices were significantly lower than the current market price (though this is not indicated in the document).
• The vesting schedules of the new options mean that the recipient must remain with the company to realize the full benefit.

Risks

• The value of the options is dependent on the future performance of Aligos Therapeutics' stock.
• Changes in employment status could impact the vesting and exercisability of the options.

Future Outlook

The document does not contain explicit forward-looking statements, but the option grants suggest an expectation of continued service from the CFO.

Industry Context

Option exchange programs are a relatively common practice in the biotech industry to incentivize employees and align their interests with those of shareholders, especially in volatile markets.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages in the biotechnology industry, often used to attract and retain talent.
• The specific terms of the options (exercise price, vesting schedule, expiration date) are generally tailored to the individual company and employee.
• Comparing the terms of these options to those offered by similar-sized biotech companies would provide a better understanding of their competitiveness.

Stakeholder Impact

• Shareholders may view the option exchange as a way to align management's interests with the company's long-term success.
• Employees may see the program as a benefit that incentivizes performance and retention.

Key Dates